Premium
DEA, SAMHSA relax OTP/OBOT regulations due to COVID‐19
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32664
Subject(s) - covid-19 , buprenorphine , methadone , flexibility (engineering) , limiting , administration (probate law) , business , enforcement , mental health , substance abuse , opioid , medicine , psychiatry , political science , virology , engineering , economics , management , mechanical engineering , receptor , disease , outbreak , law , infectious disease (medical specialty)
Opioid treatment programs (OTPs) that dispense methadone got a fast and clear reprieve from federal authorities last week in the face of COVID‐19. The Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued policies that give OTPs flexibility in take‐homes, limiting the frequency of face‐to‐face contact and opportunities for transmission of COVID‐19. There is also greater flexibility for office‐based opioid treatment (OBOT) with buprenorphine.